45 related articles for article (PubMed ID: 8700512)
1. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism.
Ohashi M; Sugikawa E; Nakanishi N
Jpn J Cancer Res; 1995 Sep; 86(9):819-27. PubMed ID: 7591958
[TBL] [Abstract][Full Text] [Related]
2. Correction: NAMPT/SIRT2-mediated inhibition of the p53-p21 signaling pathway is indispensable for maintenance and hematopoietic differentiation of human iPS cells.
Xu Y; Nasri M; Dannenmann B; Mir P; Zahabi A; Welte K; Morishima T; Skokowa J
Stem Cell Res Ther; 2023 Oct; 14(1):299. PubMed ID: 37858174
[No Abstract] [Full Text] [Related]
3. Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53.
da Costa NM; Hautefeuille A; Cros MP; Melendez ME; Waters T; Swann P; Hainaut P; Pinto LF
Cell Cycle; 2012 Dec; 11(24):4570-8. PubMed ID: 23165212
[TBL] [Abstract][Full Text] [Related]
4. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.
Wu SR; Cheng TS; Chen WC; Shyu HY; Ko CJ; Huang HP; Teng CH; Lin CH; Johnson MD; Lin CY; Lee MS
Am J Pathol; 2010 Dec; 177(6):3145-58. PubMed ID: 20971737
[TBL] [Abstract][Full Text] [Related]
5. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.
Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW
Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121
[TBL] [Abstract][Full Text] [Related]
6. Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells.
Yuan G; Qian L; Song L; Shi M; Li D; Yu M; Hu M; Shen B; Guo N
Mol Cell Biochem; 2008 Nov; 318(1-2):73-9. PubMed ID: 18600430
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Köstler WJ; Brodowicz T; Hudelist G; Rudas M; Horvat R; Steger GG; Singer CF; Attems J; Rabitsch W; Fakhrai N; Elandt K; Wiltschke C; Hejna M; Zielinski CC
J Cancer Res Clin Oncol; 2005 Jul; 131(7):420-8. PubMed ID: 15864644
[TBL] [Abstract][Full Text] [Related]
8. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling.
Zhang Y; Hamburger AW
Br J Cancer; 2005 Jan; 92(1):140-6. PubMed ID: 15583694
[TBL] [Abstract][Full Text] [Related]
9. A system for enhancing genome-wide coexpression dynamics study.
Li KC; Liu CT; Sun W; Yuan S; Yu T
Proc Natl Acad Sci U S A; 2004 Nov; 101(44):15561-6. PubMed ID: 15492223
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation.
Sheen JH; Dickson RB
Mol Cell Biol; 2002 Mar; 22(6):1819-33. PubMed ID: 11865060
[TBL] [Abstract][Full Text] [Related]
11. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
Nagy P; Jenei A; Damjanovich S; Jovin TM; Szölôsi J
Pathol Oncol Res; 1999; 5(4):255-71. PubMed ID: 10607920
[TBL] [Abstract][Full Text] [Related]
12. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.
O'Rourke DM; Kao GD; Singh N; Park BW; Muschel RJ; Wu CJ; Greene MI
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10842-7. PubMed ID: 9724792
[TBL] [Abstract][Full Text] [Related]
13. Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors.
O'Rourke DM; Greene MI
Immunol Res; 1998; 17(1-2):179-89. PubMed ID: 9479580
[TBL] [Abstract][Full Text] [Related]
14. Cyclin E, a redundant cyclin in breast cancer.
Gray-Bablin J; Zalvide J; Fox MP; Knickerbocker CJ; DeCaprio JA; Keyomarsi K
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15215-20. PubMed ID: 8986790
[TBL] [Abstract][Full Text] [Related]
15. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract][Full Text] [Related]
16. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
17. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
Park US; Park SK; Lee YI; Park JG; Lee YI
Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
[TBL] [Abstract][Full Text] [Related]
19. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
Le XF; Pruefer F; Bast RC
Cell Cycle; 2005 Jan; 4(1):87-95. PubMed ID: 15611642
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
